COST-UTILITY ANALYSIS OF NEOADJUVANT PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED, INFLAMMATORY, OR EARLY HER-2 POSITIVE BREAST CANCER

被引：0
|
作者：
Ignatyeva, V [1 ]
Khachatryan, G. [1 ]
机构：
[1] Russian Presidential Acad Natl Econ & Publ Adm, Moscow, Russia
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN173
引用
收藏
页码：A739 / A740
页数：2
相关论文
共 50 条
  • [41] Phase II neoadjuvant trial of Interferon-gamma plus weekly paclitaxel, trastuzumab and pertuzumab in patients with HER-2 positive breast cancer
    Han, Hyo S.
    Costa, Ricardo
    Armaghani, Avan
    Soyano, Aixa
    Loftus, Loretta
    Soliman, Hatem
    Fridley, Brooke
    Whiting, Junmin
    Cerezo, Aiana
    Rosa, Marilin
    Extermann, Martine
    Khong, Hung
    Czerniecki, Brian
    CANCER RESEARCH, 2022, 82 (04)
  • [42] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS PERTUZUMAB WITH TRASTUZUMAB FOR CHINESE PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER
    Guan, X.
    Li, H. C.
    Xia, Y.
    Yang, Q.
    Ma, A. X.
    VALUE IN HEALTH, 2022, 25 (07) : S372 - S372
  • [43] Costeffectiveness analysis of adjuvant trastuzumab for HER-2 positive early breast cancer in Taiwan
    Chao, T. Y.
    Chen, S. C.
    Chang, K. J.
    Chang, H. K.
    Chen, D. R.
    Hou, M. F.
    Hsieh, R. K.
    Huang, W. T.
    Tseng, L. M.
    Wang, H. C.
    Yang, L.
    Cirrincione, A.
    VALUE IN HEALTH, 2007, 10 (06) : A327 - A327
  • [44] Efficacy and safety of neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab in patients with HER2-positive early breast cancer - A retrospective study
    Koudsi, L.
    Hockaday, C.
    Levitt, N.
    Tuthill, M.
    Roux, R.
    Lord, S.
    Chiramel, J.
    CLINICAL ONCOLOGY, 2025, 38
  • [45] Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
    Kim, Ji-Yeon
    Nam, Seok Jin
    Lee, Jeong Eon
    Yu, Jonghan
    Chae, Byung Joo
    Lee, Se Kyung
    Ryu, Jai Min
    Ahn, Jin Seok
    Im, Young-Hyuck
    Kim, Seok Won
    Park, Yeon Hee
    CANCER RESEARCH AND TREATMENT, 2022, 54 (04): : 1091 - 1098
  • [46] Real Would Evidence (RWE) of neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in patients with HER2 positive early or locally advanced breast cancer treated Single institutional experience
    Kim, Ji-Yeon
    Nam, Seok Jin
    Kim, Seok Won
    Yu, Jonghan
    Chae, Byung Joo
    Lee, Se Kyung
    Ryu, Jai Min
    Ahn, Jin Seok
    Im, Young-Hyuck
    Park, Yeon Hee
    CANCER RESEARCH, 2021, 81 (04)
  • [47] Neoadjuvant pertuzumab, docetaxel, carboplatin, and trastuzumab (PTCH) regimen in patients with HER2 positive early, locally advanced, and oligometastatic breast cancer: Real-world Indian experience.
    Gogia, Ajay
    Gupta, Anshul
    Batra, Atul
    Deo, S. V. S.
    Mishra, Ashutosh
    Sharma, Daya Nand
    Saini, Surendra Kumar
    Mathur, Sandeep
    Sagiraju, Hari Krishna Raju
    Prasad, Chandra Prakash
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Neoadjuvant treatment with trastuzumab and pertuzumab plus fulvestrant in older patients with HER2-positive, ER-positive early breast cancer.
    Celis, Juan Jose
    Rodriguez, Vanessa
    Rodriguez, Crismar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 13 - 13
  • [49] Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report
    Yamashita, Yuji
    Tanaka, Yuko
    Kono, Seishi
    Nishimura, Meiko
    Mukohara, Toru
    Morinaga, Yukiko
    Hara, Shigeo
    Takao, Shintaro
    BREAST CARE, 2017, 12 (01) : 45 - 47
  • [50] Analysis of biomarkers in a pilot study of pertuzumab, trastuzumab and eribulin for advanced HER2 positive breast cancer
    Tono, Yasutaka
    Ishihara, Mikiya
    Miyahara, Yoshihiro
    Ikeda, Hiroaki
    Shiku, Hiroshi
    Shiraishi, Taizo
    Mizuno, Toshiro
    Katayama, Naoyuki
    ANNALS OF ONCOLOGY, 2016, 27
12345